BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, announced yesterday that it has named Steven M Bosacki as its new chief operating officer.
Bosacki earlier served as senior vice president and general counsel under BioPharmX CEO, Dr David S Tierney, at Oceana Therapeutics. Earlier, he served as president and CEO of Lautus Pharmaceuticals.
In his newly appointed role at BioPharmX, Bosacki will manage all operational aspects of the business including clinical, regulatory, pharmaceutical development and legal activities.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business